A detailed history of Peapack Gladstone Financial Corp transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Peapack Gladstone Financial Corp holds 493,031 shares of BMY stock, worth $28.3 Million. This represents 0.37% of its overall portfolio holdings.

Number of Shares
493,031
Previous 563,342 12.48%
Holding current value
$28.3 Million
Previous $23.4 Million 9.04%
% of portfolio
0.37%
Previous 0.36%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 26, 2024

SELL
$39.66 - $51.75 $2.79 Million - $3.64 Million
-70,311 Reduced 12.48%
493,031 $25.5 Million
Q2 2024

Aug 13, 2024

SELL
$40.25 - $52.99 $621,500 - $818,218
-15,441 Reduced 2.67%
563,342 $23.4 Million
Q1 2024

May 10, 2024

SELL
$47.98 - $54.4 $1.12 Million - $1.27 Million
-23,312 Reduced 3.87%
578,783 $31.4 Million
Q4 2023

Feb 13, 2024

SELL
$48.48 - $57.85 $1.55 Million - $1.85 Million
-32,032 Reduced 5.05%
602,095 $30.9 Million
Q3 2023

Nov 14, 2023

SELL
$57.89 - $64.73 $207,419 - $231,927
-3,583 Reduced 0.56%
634,127 $36.8 Million
Q2 2023

Aug 14, 2023

SELL
$63.71 - $70.74 $627,224 - $696,435
-9,845 Reduced 1.52%
637,710 $40.8 Million
Q1 2023

May 15, 2023

BUY
$65.71 - $74.53 $204,752 - $232,235
3,116 Added 0.48%
647,555 $45.3 Million
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $733,900 - $869,041
10,717 Added 1.69%
644,439 $46.4 Million
Q3 2022

Nov 10, 2022

BUY
$0.13 - $76.84 $4,876 - $2.88 Million
37,510 Added 6.29%
633,722 $45.1 Million
Q2 2022

Aug 12, 2022

BUY
$72.62 - $79.98 $1.03 Million - $1.14 Million
14,197 Added 2.44%
596,212 $45.9 Million
Q1 2022

May 16, 2022

BUY
$61.48 - $73.72 $361,379 - $433,326
5,878 Added 1.02%
582,015 $42.5 Million
Q4 2021

Feb 15, 2022

BUY
$53.63 - $62.52 $48,696 - $56,768
908 Added 0.16%
576,137 $35.9 Million
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $1.96 Million - $2.3 Million
33,175 Added 6.12%
575,229 $34 Million
Q2 2021

Aug 16, 2021

SELL
$61.91 - $67.42 $498,065 - $542,393
-8,045 Reduced 1.46%
542,054 $36.2 Million
Q1 2021

May 14, 2021

SELL
$59.34 - $66.74 $473,829 - $532,918
-7,985 Reduced 1.43%
550,099 $34.7 Million
Q4 2020

Feb 16, 2021

BUY
$57.74 - $65.43 $200,184 - $226,845
3,467 Added 0.63%
558,084 $34.6 Million
Q3 2020

Nov 16, 2020

SELL
$57.43 - $63.64 $601,062 - $666,056
-10,466 Reduced 1.85%
554,617 $33.4 Million
Q2 2020

Aug 14, 2020

BUY
$54.82 - $64.09 $925,745 - $1.08 Million
16,887 Added 3.08%
565,083 $33.2 Million
Q1 2020

May 15, 2020

BUY
$46.4 - $67.43 $1.66 Million - $2.41 Million
35,770 Added 6.98%
548,196 $30.6 Million
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $4.31 Million - $5.62 Million
87,606 Added 20.62%
512,426 $32.9 Million
Q3 2019

Nov 13, 2019

SELL
$42.77 - $50.71 $108,935 - $129,158
-2,547 Reduced 0.6%
424,820 $21.5 Million
Q2 2019

Aug 15, 2019

BUY
$44.62 - $49.34 $1.91 Million - $2.11 Million
42,701 Added 11.1%
427,367 $19.4 Million
Q1 2019

May 15, 2019

BUY
$45.12 - $53.8 $1.95 Million - $2.32 Million
43,193 Added 12.65%
384,666 $18.4 Million
Q4 2018

Feb 14, 2019

BUY
$48.76 - $63.23 $1.53 Million - $1.98 Million
31,313 Added 10.1%
341,473 $17.8 Million
Q3 2018

Nov 14, 2018

SELL
$55.19 - $62.25 $108,337 - $122,196
-1,963 Reduced 0.63%
310,160 $19.3 Million
Q2 2018

Aug 09, 2018

BUY
$50.53 - $62.98 $426,675 - $531,803
8,444 Added 2.78%
312,123 $17.3 Million
Q1 2018

May 10, 2018

SELL
$59.92 - $68.98 $410,931 - $473,064
-6,858 Reduced 2.21%
303,679 $0
Q4 2017

Feb 14, 2018

BUY
$59.94 - $65.35 $1.12 Million - $1.22 Million
18,663 Added 6.39%
310,537 $0
Q3 2017

Nov 14, 2017

BUY
$55.23 - $63.74 $570,084 - $657,924
10,322 Added 3.67%
291,874 $0
Q2 2017

Aug 14, 2017

BUY
N/A
281,552
281,552 $0

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $122B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Peapack Gladstone Financial Corp Portfolio

Follow Peapack Gladstone Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Peapack Gladstone Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Peapack Gladstone Financial Corp with notifications on news.